Trust Co. of Oklahoma Decreases Stake in Danaher Co. (NYSE:DHR)

Trust Co. of Oklahoma cut its holdings in shares of Danaher Co. (NYSE:DHR) by 2.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 24,896 shares of the conglomerate’s stock after selling 616 shares during the period. Danaher makes up 1.8% of Trust Co. of Oklahoma’s portfolio, making the stock its 13th biggest position. Trust Co. of Oklahoma’s holdings in Danaher were worth $5,715,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Decker Retirement Planning Inc. bought a new position in shares of Danaher during the 4th quarter valued at $31,000. Teachers Insurance & Annuity Association of America purchased a new stake in Danaher during the third quarter valued at $39,000. MidAtlantic Capital Management Inc. bought a new position in Danaher in the third quarter valued at about $40,000. FSA Wealth Management LLC purchased a new position in Danaher in the third quarter worth about $50,000. Finally, Darwin Wealth Management LLC bought a new stake in shares of Danaher during the 3rd quarter valued at about $55,000. 79.05% of the stock is currently owned by institutional investors.

Danaher Stock Performance

Shares of NYSE DHR opened at $244.19 on Thursday. The company has a market cap of $176.38 billion, a P/E ratio of 46.60, a P/E/G ratio of 4.43 and a beta of 0.83. Danaher Co. has a 52-week low of $225.42 and a 52-week high of $281.70. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The firm’s fifty day moving average is $234.90 and its two-hundred day moving average is $253.47.

Danaher (NYSE:DHR) last issued its earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The firm had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the previous year, the firm posted $2.02 earnings per share. The business’s revenue was up 3.1% compared to the same quarter last year. As a group, analysts anticipate that Danaher Co. will post 7.5 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be issued a dividend of $0.27 per share. The ex-dividend date is Friday, December 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. Danaher’s dividend payout ratio (DPR) is 20.61%.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on DHR shares. KeyCorp increased their price objective on shares of Danaher from $290.00 to $310.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 23rd. Stifel Nicolaus lifted their price target on shares of Danaher from $250.00 to $265.00 and gave the stock a “hold” rating in a research note on Wednesday, October 23rd. Royal Bank of Canada reduced their price objective on Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. TD Cowen lifted their target price on Danaher from $310.00 to $315.00 and gave the company a “buy” rating in a research report on Wednesday, October 23rd. Finally, Scotiabank assumed coverage on Danaher in a research report on Monday, December 23rd. They issued a “sector perform” rating and a $265.00 price target for the company. Six equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $285.55.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.